(firstQuint)Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer.

 PRIMARY OBJECTIVE: To determine whether neoadjuvant docetaxel and carboplatin will increase the pCR rate in TNBC compared to historical controls.

 Pathologic complete response (pCR) will be defined as no residual invasive breast cancer in the breast and ipsilateral axillary lymph node (ypT0-is ypN0).

.

 Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer@highlight

The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.

